Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.
News|Articles|March 30, 2026
Q2 2026 preview: 4 FDA decisions to watch in pediatric care
Author(s)Celeste Krewson, Assistant Editor
Fact checked by: Yasmeen Qahwash
A review of 4 drugs to be discussed by the US FDA during Q2 2026, with links to coverage from MJH Life Sciences publications.
Advertisement
Advertisement
The second quarter of 2026 will include multiple advancements in pediatric care, including 4 drugs to be discussed by the FDA that will significantly advance disease management in this population. These include inhaled insulin (Afrezza), a rapid-acting inhaled human insulin for glycemic control, and teplizumab (Tzield), a disease-modifying intervention to delay the onset of type 1 diabetes.
Related to this article
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
Diana F. Clarke, PharmD, explains how IMPAACT 2023 supported dolutegravir from birth, plus dosing tips and open questions for preterm infants.
New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
Advertisement
Advertisement